Targeting Th2 cytokines in fibrotic diseases

Current Opinion in Investigational Drugs

Volumn 11, Issue 11, 2010, Pages 1229-1238

  Morishima, Yuko ^a   Ishii, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Asthma; GATA 3; IFN ; IL 13; IL 4; liver fibrosis; pulmonary fibrosis; STAT; systemic sclerosis; T helper cell; Th1; Th2

Indexed keywords

AEROVANCE; ALTRAKINCEPT; AMG 317; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTEFERON 1B; GAMMA INTERFERON; GAMMA INTERFERON DERIVATIVE; GLUCOCORTICOID; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MEPOLIZUMAB; PITRAKINRA; PLACEBO; RECOMBINANT GAMMA INTERFERON; RESLIZUMAB; TRALOKINUMAB; UNCLASSIFIED DRUG;

AIRWAY REMODELING; ALLERGIC ASTHMA; ASTHMA; ATOPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG TARGETING; FIBROSIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY FIBROSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG FIBROSIS; META ANALYSIS (TOPIC); MUSCLE SPASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 78650388906     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Bhogal RK, Stoica CM, McGaha TL, Bona CA: Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol (2005) 25(6):592-603.
2. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest (1992) 90(4):1479-1485.
3. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 214(2):199-210.
4. Foster W, Li Y, Usas A, Somogyi G, Huard J: γ Interferon as an antifibrosis agent in skeletal muscle. J Orthop Res (2003) 21(5):798-804.
5. Zhu J, Yamane H, Paul WE: Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 28:445-489.
6. Amsen D, Spilianakis CG, Flavell RA: How are Th1 and Th2 effector cells made? Curr Opin Immunol (2009) 21(2):153-160.
7. Zhu J, Paul WE: CD4 T cells: Fates, functions, and faults. Blood (2008) 112(5):1557-1569.
8. Ichinose K, Kawasaki E, Eguchi K: Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol (2007) 27(6):554-564.
9. Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F: Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. Autoimmun Rev (2005) 4(8):542-548.
10. Lubberts E: Th17 cytokines and arthritis. Semin Immunopathol (2010) 32(1):43-53.
11. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M: Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev (2008) 226:87-102.
12. Segal BM: Th17 cells in autoimmune demyelinating disease. Semin Immunopathol (2010) 32(1):71-77.
13. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M: Importance of cytokines in murine allergic airway disease and human asthma. J Immunol (2010) 184(4): 1663-1674.
14. Paul WE: What determines Th2 differentiation, in vitro and ? Immunol Cell Biol (2010) 88(3):236-239.
15. Zhu J: Transcriptional regulation of Th2 cell differentiation. Immunol Cell Biol (2010) 88(3):244-249.
16. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE: GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res (2006) 16(1):3-10.
17. Usui T, Nishikomori R, Kitani A, Strober W: GATA-3 suppresses Th1 development by downregulation of STAT4 and not through effects on IL-12Rβ2 chain or T-bet. Immunity (2003) 18(3):415-428.
18. Siegel MD, Zhang DH, Ray P, Ray A: Activation of the interleukin-5 promoter by cAMP in murine EL-4 cells requires the GATA-3 and CLE0 elements. J Biol Chem (1995) 270(41): 24548-24555.
19. Yamashita M, Ukai-Tadenuma M, Kimura M, Omori M, Inami M, Taniguchi M, Nakayama T: Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J Biol Chem (2002) 277(44): 42399-42408.
20. Agarwal S, Avni O, Rao A: Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Immunity (2000) 12(6):643-652.
21. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100(6):655-669.
22. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, Reiner SL: Role of T-bet in commitment of Th1 cells before IL-12-dependent selection. Science (2001) 292(5523):1907-1910.
23. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream JH, O'Shea JJ, Strober W: T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med (2006) 203(3):755-766.
24. Kaplan MH, Sun YL, Hoey T, Grusby MJ: Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature (1996) 382(6587):174-177.
25. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN: Requirement for STAT4 in interleukin-12-mediated responses of natural killer and T cells. Nature (1996) 382(6587):171-174.
26. Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, Centola M, Wu CY, Yamada N, El Gabalawy H, O'Shea JJ: STAT4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol (2000) 164(9):4659-4664.
27. Thieu VT, Qing Yu Q, Chang HC, Yeh N, Nguyen ET, Sehra S, Kaplan MH: Stat4 is required for T-bet to promote IL-12- dependent Th1 fate determination. Immunity (2008) 29(5): 679-690.
28. Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, Murphy TL, Murphy KM: T-bet is a STAT1-induced regulator of IL-12R expression in nave CD4+ T cells. Nat Immunol (2002) 3(6):549-557.
29. Zhu J, Cote-Sierra J, Guo L, Paul WE: STAT5 activation plays a critical role in Th2 differentiation. Immunity (2003) 19(5): 739-748.
30. Kaplan MH, Schindler U, Smiley ST, Grusby MJ: STAT6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity (1996) 4(3):313-319.
31. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 cells. Annu Rev Immunol (2009) 27:485-517.
32. Damsker JM, Hansen AM, Caspi RR: Th1 and Th17 cells: Adversaries and collaborators. Ann NY Acad Sci (2010) 1183: 211-221.
33. Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 22:531-562.
34. Shevach EM: Mechanisms of Foxp3+ T regulatory cellmediated suppression. Immunity (2009) 30(5):636-645.
35. Afzali B, Lombardi G, Lechler RI, Lord GM: The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol (2007) 148(1):32-46.
36. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA: Role of Treg in immune regulation of allergic diseases. Eur J Immunol (2010) 40(5):1232-1240.
37. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury S et al: IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3- effector T cells. Nat Immunol (2008) 9(12):1347-1355.
38. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, Martin B, Wilhelm C, Stockinger B: Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 9(12):1341-1346.
39. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ: Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol (2010) 88(6):624-631.
40. Godfrey DI, Stankovic S, Baxter AG: Raising the NKT cell family. Nat Immunol (2010) 11(3):197-206.
41. Saenz SA, Taylor BC, Artis D: Welcome to the neighborhood: Epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev (2008) 226:172-190.
42. Barrett NA, Austen KF: Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 31(3): 425-437.
43. Angkasekwinai P, Park H, Wang YH, Wang YH, Chang SH, Corry DB, Liu YJ, Zhu Z, Dong C: Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med (2007) 204(7):1509-1517.
44. He R, Geha RS: Thymic stromal lymphopoietin. Ann NY Acad Sci (2010) 1183:13-24.
45. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D: Pivotal a dvance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol (2008) 83(6):1323-1333.
46. Postlethwaite AE, Seyer JM: Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest (1991) 87(6):2147-2152.
47. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA: An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest (1999) 104(6):777-785.
48. Kolodsick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A, Wilke CA, Chrisman CJ, Moore BB: Protection from fluorescein isothiocyanate-induced fibrosis in IL-13- deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol (2004) 172(7): 4068-4076.
49. Blease K, Schuh JM, Jakubzick C, Lukacs NW, Kunkel SL, Joshi BH, Puri RK, Kaplan MH, Hogaboam CM: STAT6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol (2002) 160(2):481-490.
50. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A: IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med (2006) 12(1):99-106.
51. Reiman RM, Thompson RW, Feng CG, Hari D, Knight R, Cheever AW, Rosenberg HF, Wynn TA: Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun (2006) 74(3):1471-1479.
52. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, Cheever AW, Young DA, Collins M, Grusby MJ, Wynn TA: The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest (2006) 116(7):2044-2055.
53. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, Bourne PA, Pierce RH, Kastelein R, Pflanz S: IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2010) 184(3):1526-1535.
54. Saito A, Okazaki H, Sugawara I, Yamamoto K, Takizawa H: Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol (2003) 132(2):168-176.
55. Bellini A, Mattoli S: The role of the fibrocyte, a bone marrowderived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest (2007) 87(9):858-870.
56. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, Barbarin V, Renauld JC, Lison D: Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. Am J Respir Cell Mol Biol (2001) 24(4):368-375.
57. van den Brle S, Heymans J, Havaux X, Renauld JC, Lison D, Huaux F, Denis O: Profibrotic effect of IL-9 overexpression in a model of airway remodeling. Am J Respir Cell Mol Biol (2007) 37(2):202-209.
58. Wynn TA: Fibrotic disease and the Th1/Th2 paradigm. Nat Rev Immunol (2004)4(8):583-594.
59. Harari S, Caminati A: IPF: New insight on pathogenesis and treatment. Allergy (2010) 65(5):537-553.
60. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis (1979) 120(4):893-899.
61. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol (1999) 65(2):187-195.
62. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med (1989) 170(3):655-663.
63. Schrier DJ, Phan SH, McGarry BM: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis (1983) 127(5): 614-617.
64. Okazaki T, Nakao A, Nakano H, Takahashi F, Takahashi K, Shimozato O, Takeda K, Yagita H, Okumura K: Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol (2001) 167(4):1977-1981.
65. Kimura T, Ishii Y, Yoh K, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Homma S, Nomura A, Sakamoto T, Takahashi S et al: Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am J Pathol (2006) 169(1):96-104.
66. Xu J, Mora AL, LaVoy J, Brigham KL, Rojas M: Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet. Am J Physiol Lung Cell Mol Physiol (2006) 291(4):L658-L667.
67. Kikuchi N, Ishii Y, Morishima Y, Yageta Y, Haraguchi N, Itoh K, Yamamoto M, Hizawa N: Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. Respir Res (2010) 11:31.
68. Papiris SA, Kollintza A, Kitsanta P, Kapotsis G, Karatza M, Milic-Emili J, Roussos C, Daniil Z: Relationship of BAL and lung tissue CD4+ and CD8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest (2005) 128(4):2971-2977.
69. Pignatti P, Brunetti G, Moretto D, Yacoub MR, Fiori M, Balbi B, Balestrino A, Cervio G, Nava S, Moscato G: Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med (2006) 173(3):310-317.
70. Global strategy for asthma management and prevention: Global Initiative for Asthma (GINA) (2009). www.ginasthma.org
71. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR: Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1990) 3(5):507-511.
72. Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, O'Byrne PM, Inman MD: Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med (2004) 169(7):860-867.
73. Elias JA, Zheng T, Lee CG, Homer RJ, Chen Q, Ma B, Blackburn M, Zhu Z: Transgenic modeling of interleukin-13 in the lung. Chest (2003) 123(3 Suppl):339S-345S.
74. Kiwamoto T, Ishii Y, Morishima Y, Yoh K, Maeda A, Ishizaki K, Iizuka T, Hegab AE, Matsuno Y, Homma S, Nomura A et al: Transcription factors T-bet and GATA-3 regulate development of airway remodeling. Am J Respir Crit Care Med (2006) 174(2):142-151.
75. Marra F, Aleffi S, Galastri S, Provenzano A: Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 31(3):345-358
76. Shi Z, Wakil AE, Rockey DC: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA (1997) 94(20):10663-10668.
77. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A: Interferon γ decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology (1996) 23(5):1189-1199.
78. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A: An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature (1995) 376(6541):594-596.
79. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, Cox TM, Hieny S, Caspar P, Sher A: Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol (1994) 153(2):753-759.
80. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA: Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology (2001) 34(2):273-282.
81. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, Glimcher LH: Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA (2007) 104(8):2827-2830.
82. Chizzolini C: T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol (2008) 20(6):707-712.
83. Meloni F, Solari N, Cavagna L, Morosini M, Montecucco CM, Fietta AM: Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol (2009) 27(5):765-772.
84. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE: Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med (1993) 119(12): 1198-1208.
85. Gurujeyalakshmi G, Giri SN: Molecular mechanisms of antifibrotic effect of interferon γ in bleomycin-mouse model of lung fibrosis: Downregulation of TGF-β and procollagen I and III gene expression. Exp Lung Res (1995) 21(5):791-808.
86. Oldroyd SD, Thomas GL, Gabbiani G, El Nahas AM: Interferon-γ inhibits experimental renal fibrosis. Kidney Int (1999) 56(6): 2116-2127.
87. Yamamoto T, Takagawa S, Kuroda M, Nishioka K: Effect of interferon-gamma on experimental scleroderma induced by bleomycin. Arch Dermatol Res (2000) 292(7):362-365.
88. Keane MP, Belperio JA, Burdick MD, Strieter RM: IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2001) 281(1):L92-L97.
89. Kumar RK, Herbert C, Webb DC, Li L, Foster PS: Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med (2004) 170(10):1043-1048.
90. Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A: Interferon-γ1b therapy in idiopathic pulmonary fibrosis: A metaanalysis. Chest (2005) 128(1):203-206.
91. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmonary Fibrosis Study Group: A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 350(2):125-133.
92. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D et al: Effect of interferon γ-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet (2009) 374(9685):222-228.
93. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM et al: Final results of a double-blind, placebocontrolled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology (2007) 45(3):569-578.
94. Kahan A, Amor B, Menkes CJ, Strauch G: Recombinant interferon-γ in the treatment of systemic sclerosis. Am J Med (1989) 87(3):273-277.
95. Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, Galaris D, Papiris SA, Moutsopoulos HM: Safety and efficacy of recombinant γ interferon in the treatment of systemic sclerosis. Ann Rheum Dis (1996) 55(10):761-768.
96. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, Salmhofer W, Zahel B, Pinter G, Herold M, Klein G et al: Interferon-γ in the treatment of systemic sclerosis: A randomized controlled multicentre trial. Br J Dermatol (1998) 139(4):639-648.
97. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS: A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: Effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol (1996) 23(4):654-658.
98. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM, IL-4R Asthma Study Group: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol (2001) 107(6):963-970.
99. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet (2007) 370(9596):1422-1431.
100. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med (2003) 167(12):1655-1659.
101. Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB: Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol (2004) 122(6):1406-1412.
102. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest (2003) 112(7):1029-1036.
103. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med (2010) 10:3.
104. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL: A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med (2010) 181(8):788-796.
105. Walker BL, Leigh R: Use of biologicals as immunotherapy in asthma and related diseases. Expert Rev Clin Immunol (2008) 4(6):743-756.